How to increase haematologists’ and oncologists’ confidence with new treatmentsA new whitepaper from Medscape highlights the difficulties haematologists and oncologists face in keeping up with rapid developments Share XHow to increase haematologists’ and oncologists’ confidence with new treatmentshttps://deep-dive.pharmaphorum.com/magazine/future-of-oncology-2020/how-to-increase-haematologists-and-oncologists-confidence-with-new-treatments/
Clinical decision-making insights for haem/oncsDespite the effects of countries’ lockdown policies, a plethora of clinical trial readouts continue to emerge providing several Share XClinical decision-making insights for haem/oncshttps://pharmaphorum.com/oncology/clinical-decision-making-insights-haem-oncs/
Scopus Bio preps trials of gene-silencing immuno-oncology drugScopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start Share XScopus Bio preps trials of gene-silencing immuno-oncology drughttps://pharmaphorum.com/news/scopus-bio-preps-trials-of-gene-silencing-immuno-oncology-drug/
AbbVie forges $3.9 billion oncology alliance with GenmabAbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed Share XAbbVie forges $3.9 billion oncology alliance with Genmabhttps://pharmaphorum.com/news/abbvie-forges-3-9-billion-oncology-alliance-with-genmab/
Menarini bags blood cancer drug with $677M Stemline acquisitionItalian drugmaker Menarini has agreed to buy Stemline Therapeutics, bolting on an already-approved drug for a rare form Share XMenarini bags blood cancer drug with $677M Stemline acquisitionhttps://pharmaphorum.com/news/menarini-bags-blood-cancer-drug-with-677m-stemline-acquisition/
CHMP backs BMS’ first-in-class anaemia drug ReblozylBristol-Myers Squibb has moved a step closer to EMA approval of Reblozyl, a therapy for anaemia that has Share XCHMP backs BMS’ first-in-class anaemia drug Reblozylhttps://pharmaphorum.com/news/chmp-backs-bms-first-in-class-anaemia-drug-reblozyl/
J&J defends Darzalex with FDA approval for faster dosingJohnson & Johnson has claimed FDA approval for new formulation of its blockbuster multiple myeloma drug Darzalex that Share XJ&J defends Darzalex with FDA approval for faster dosinghttps://pharmaphorum.com/news/jj-defends-darzalex-with-fda-approval-for-faster-dosing/
BMS preps filings for leukaemia maintenance therapy CC-486Celgene’s pipeline has delivered another new drug filing for Bristol-Myers Squibb, thanks to positive results for oral azacitidine Share XBMS preps filings for leukaemia maintenance therapy CC-486https://pharmaphorum.com/news/bms-preps-filings-for-leukaemia-maintenance-therapy-cc-486/
Real-world data backs Kymriah’s safety profile, says NovartisWith more competition looming for its CAR-T therapy Kymriah, Novartis has pointed to new data that show the Share XReal-world data backs Kymriah’s safety profile, says Novartishttps://pharmaphorum.com/news/real-world-data-backs-kymriahs-safety-profile-says-novartis/
